{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:55:36Z","timestamp":1763348136879},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jtho.2018.06.008","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:03:58Z","timestamp":1530144238000},"page":"1577-1587","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates"],"prefix":"10.1016","volume":"13","author":[{"given":"Laurel M.","family":"Schunselaar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Monkhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruud","family":"Wijdeven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Neefjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2018.06.008_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0003-4975(10)60182-8","article-title":"Pleural mesothelioma","volume":"43","author":"Martini","year":"1987","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2018.06.008_bib2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ctrv.2012.12.005","article-title":"Malignant mesothelioma: new insights into a rare disease","volume":"39","author":"Remon","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2018.06.008_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2486\/indhealth.39.183","article-title":"Pathology of human malignant mesothelioma\u2013preliminary analysis of 1,517 mesothelioma cases","volume":"39","author":"Suzuki","year":"2001","journal-title":"Industrial Health"},{"key":"10.1016\/j.jtho.2018.06.008_bib4","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtho.2018.06.008_bib5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.008_bib6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2018.06.008_bib7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtho.2018.06.008_bib8","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","article-title":"Evolving strategies for target selection for antibody-drug conjugates","volume":"32","author":"Damelin","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.jtho.2018.06.008_bib9","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing","volume":"66","author":"Erickson","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.008_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1517\/13543784.2011.582866","article-title":"Investigational antibody drug conjugates for solid tumors","volume":"20","author":"Sapra","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jtho.2018.06.008_bib11","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.bmcl.2014.10.021","article-title":"Antibody-drug conjugates-a new wave of cancer drugs","volume":"24","author":"Bouchard","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jtho.2018.06.008_bib12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.str.2014.01.009","article-title":"Structural insights into the inhibition of Wnt signaling by cancer antigen 5T4\/Wnt-activated inhibitory factor 1","volume":"22","author":"Zhao","year":"2014","journal-title":"Structure"},{"key":"10.1016\/j.jtho.2018.06.008_bib13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.devcel.2011.10.015","article-title":"Waif1\/5T4 inhibits Wnt\/beta-catenin signaling and activates noncanonical Wnt pathways by modifying LRP6 subcellular localization","volume":"21","author":"Kagermeier-Schenk","year":"2011","journal-title":"Dev Cell"},{"key":"10.1016\/j.jtho.2018.06.008_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/(SICI)1097-0215(19960927)68:1<84::AID-IJC15>3.0.CO;2-6","article-title":"Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells","volume":"68","author":"Carsberg","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2018.06.008_bib15","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1091\/mbc.e06-09-0875","article-title":"E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells","volume":"18","author":"Spencer","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jtho.2018.06.008_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1988.53","article-title":"A\u00a072 kD trophoblast glycoprotein defined by a monoclonal antibody","volume":"57","author":"Hole","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.06.008_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcancer.2014.07.004","article-title":"Understanding and exploiting 5T4 oncofoetal glycoprotein expression","volume":"29","author":"Stern","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jtho.2018.06.008_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/bjc.1990.20","article-title":"Immunohistological distribution of 5T4 antigen in normal and malignant tissues","volume":"61","author":"Southall","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.06.008_bib19","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1158\/0008-5472.CAN-10-3919","article-title":"Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells","volume":"71","author":"Damelin","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.008_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1525-1438.1995.05040269.x","article-title":"5T4 oncofetal antigen expression in ovarian carcinoma","volume":"5","author":"Wrigley","year":"1995","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jtho.2018.06.008_bib21","first-page":"1033","article-title":"Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer","volume":"22","author":"Naganuma","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2018.06.008_bib22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/bjc.1994.173","article-title":"Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma","volume":"69","author":"Starzynska","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.06.008_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10637-016-0419-7","article-title":"First-in-human trial of an anti-5T4 antibody-monomethylauristatin\u00a0conjugate, PF-06263507, in patients with advanced solid tumors","volume":"35","author":"Shapiro","year":"2017","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.jtho.2018.06.008_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/1535-7163.MCT-12-0603","article-title":"Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells","volume":"12","author":"Sapra","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2018.06.008_bib25","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.lungcan.2012.03.008","article-title":"Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma","volume":"77","author":"Al-Taei","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.06.008_bib26","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1078-0432.CCR-17-1345","article-title":"Chemical profiling of primary mesothelioma cultures defines subtypes with different expression profiles and clinical responses","volume":"24","author":"Schunselaar","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.008_bib27","first-page":"221","article-title":"The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin","volume":"32","author":"Boghaert","year":"2008","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jtho.2018.06.008_bib28","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1021\/bc800289a","article-title":"Novel peptide linkers for highly potent antibody-auristatin conjugate","volume":"19","author":"Doronina","year":"2008","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.jtho.2018.06.008_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijc.2910350302","article-title":"Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NKI\/C-3","volume":"35","author":"Vennegoor","year":"1985","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2018.06.008_bib30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2018.06.008_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials","volume":"23","author":"Fennell","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.008_bib32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.jtho.2018.06.008_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","article-title":"Lysosomes as mediators of drug resistance in cancer","volume":"24","author":"Zhitomirsky","year":"2016","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jtho.2018.06.008_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcp.2016.07.012","article-title":"New therapeutic strategies for malignant pleural mesothelioma","volume":"123","author":"Bonelli","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jtho.2018.06.008_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ctrv.2014.10.007","article-title":"Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies","volume":"41","author":"Remon","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2018.06.008_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2018.06.008_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat Biotech"},{"key":"10.1016\/j.jtho.2018.06.008_bib38","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.008_bib39","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2018.06.008_bib40","doi-asserted-by":"crossref","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.328","article-title":"Randomized phase II study of anetumab ravtansine or vinorelbine in patients with malignant pleural mesothelioma","volume":"12","author":"Kindler","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.06.008_bib41","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/mt.2015.207","article-title":"Receptor crosslinking in drug delivery: detour to the lysosome?","volume":"23","author":"Ogris","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtho.2018.06.008_bib42","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1080\/15548627.2015.1085742","article-title":"Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux","volume":"11","author":"Giuliano","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.jtho.2018.06.008_bib43","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"Muller","year":"2014","journal-title":"Cancer Immunol Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418307172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418307172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T01:37:27Z","timestamp":1569893847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086418307172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1556086418307172"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2018.06.008","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}